HLAII peptide presentation of infliximab increases when complexed with TNF

CD4+ T-cell activation through recognition of Human Leukocyte Antigen II (HLAII)-presented peptides is a key step in the development of unwanted immune response against biotherapeutics, such as the generation of anti-drug antibodies (ADA). Therefore, the identification of HLAII-presented peptides de...

Descripción completa

Detalles Bibliográficos
Autores principales: Casasola-LaMacchia, Andrea, Seward, Robert Joseph, Tourdot, Sophie, Willetts, Matthew, Kruppa, Gary, Agostino, Michael J., Bergeron, Gabrielle, Ahyi-Amendah, Nathalie, Ciarla, Andrew, Lu, Zhaojiang, Kim, Hai-Young, Hickling, Timothy P., Neubert, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513746/
https://www.ncbi.nlm.nih.gov/pubmed/36177046
http://dx.doi.org/10.3389/fimmu.2022.932252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513746/
https://www.ncbi.nlm.nih.gov/pubmed/36177046
http://dx.doi.org/10.3389/fimmu.2022.932252

Ejemplares similares